Acarbose vs CagriSema
A side-by-side research comparison of Acarbose and CagriSema across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Acarbose | CagriSema |
|---|---|---|
| Full name | Acarbose (Alpha-Glucosidase Inhibitor) | CagriSema (Cagrilintide + Semaglutide) |
| Category | Weight Management | Weight Management |
| Status | FDA-approved drug | Phase 3 Clinical Trial |
| Mechanism | Inhibits intestinal alpha-glucosidase enzymes, slowing the breakdown of complex carbohydrates into glucose. This flattens post-prandial glucose and insulin excursions and shifts undigested carbohydrate to the colon, feeding beneficial short-chain-fatty-acid-producing bacteria. | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. |
| Molecular weight | 645.6 Da | Combination product |
| Half-life | ~2 hours | 7 days (both components) |
| Bioavailability | Very low systemic (~2%); acts locally in the gut | High (SubQ) |
| Typical dose | 25-100 mg per meal | Cagrilintide 2.4mg + Semaglutide 2.4mg |
| Frequency | With carbohydrate-containing meals | Once weekly |
| Route | Oral tablet | Subcutaneous |
Acarbose reported benefits
- Flattens post-meal glucose spikes
- Improves glycemic variability
- Longevity signal (ITP data)
- Feeds beneficial gut bacteria
- Modest weight support
- Minimal systemic absorption
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Related comparisons
Research and educational reference only. Not medical advice.